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 KAJIAN PERBANDINGAN KE AS SEL MCF-7 INDUK DAN RESISTAN 
TERAHADAP KARAKTERISTIK MIGRASI YANG BERKAIT DENGAN 
RAWATAN KACA BIOAKTIF 
ABSTRAK 
Pengenalan: Kanser payudara adalah salah satu punca utama kematian di seluruh 
dunia, terutamanya dalam kalangan wanita. Ia menyumbang satu pertiga daripada 
kematian dan merupakan kanser kedua yang paling umum di dunia. Kaca bioaktif (BG) 
45S5 digunakan terutamanya dalam bidang ortopedik dan pergigian untuk pertumbuhan 
semula tulang dan tisu. Baru-baru ini, ia diuji sebagai kaedah penyampaian ubat terutama 
dalam terapi kanser. Objektif: Untuk melakukan kajian perbandingan terhadap migrasi 
titisan sel induk and titisan sel resistan kanser payudara (MCF-7) dengan rawatan 4555 
kaca bioaktif. Kaedah: BG telah disintesis menggunakan kaedah sol-gel. Cerakinan 
penyembuhan luka telah dilakukan untuk menentukan penutupan kawasan luka pada 
masa berlainan. Setiap titisan sel ditanam dalam plat 24-ruang dan dirawat dengan 
kepekatan BG yang berbeza dan vinblastine ubat kemoterapi piawai. Data yang diperolehi 
dianalisa menggunakan Image J. Keputusan dan Perbincangan: Penemuan mencadangkan 
2 mg/ml BG menggalakkan penghijrahan dan percambahan titisan sel induk dan sel 
resistan MCF-7 kanser payudara. Pada kepekatan yang lebih tinggi iaitu 4 mg/ml BG, 8 
mg/ml BG dan vinblastine, ia menyebabkan perencatan titisan sel MCF- 7 induk dan 
resistan. Hasil kajian menunjukkan tiada perbezaan yang ketara kawasan penyembuhan 
luka antara kawalan dan 2 mg/ml BG. Namun perbezaan yang signifikan dikesan antara 
kawalan serta titisan sel induk dan resistan setelah dirawat dengan 4 mg/ml BG, 8 mg/ml 
BG dan vinblastine. Sementara itu, tiada perbezaan yang signit;ifikan antara ≥ 4 mg/ml 
BG sel dirawat dan vinblastine. Kesimpulan: Migrasi sel kanser payudara induk dan 
 xvii 
 
resistan dapat dikawal dengan rawatan BG pada kepekatan ≥ 4 mg/ml atau diberi sebagai 
adjung dengan drug kemoterapi piawai 
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A COMPARATIVE STUDY ON PARENT AND RESISTANT MCF-7 CELLS ON 
MIGRATION CHARACTERISTICS WITH REGARDS TO BIOACTIVE 
GLASS TREATMENT 
 
ABSTRACT 
Introduction: Breast cancer is one of the leading causes of mortality worldwide, 
particularly among women. It accounts for one third of mortality and is the second most 
common cancer in the world. The 45S5 bioactive glass (BG) is predominantly used in the 
orthopaedic and dentistry field for bone and tissue regeneration. Recently, it is being 
tested as a mode of drug delivery particularly in cancer therapy.  Objective: To perform 
a comparative study on parent and resistant breast cancer cell lines (MCF-7) migration 
with 4555 bioactive glass. Methods: BG was synthesised using sol-gel method. Wound 
healing assay was done to determine closure of wound area at different time-points. Each 
cell line was grown in 24-well plates and treated with different concentration of BG and 
standard chemotherapy drug vinblastine. Wound area was analysed using Image J and 
repeated measures ANOVA used to analyse the obtained data. Results and Discussion: 
Findings suggest 2 mg/ml BG promoted migration and migration of parent and resistant 
MCF- 7 breast cancer cells. While at higher concentration with 4 mg/ml BG, 8 mg/ml BG 
and vinblastine caused inhibition of parent and resistant MCF-7. There was no significant 
difference of closure area between the controls and 2 mg/ml BG treated cells. Significant 
difference was detected between the controls of parent and resistant MCF-7 cells with 4 
mg/ml BG, 8 mg/ml BG and vinblastine treated breast cancer cells. Furthermore, there 
was no significant difference between ≥ 4 mg/ml BG treated cells and vinblastine. 
Conclusion: Bioactive glass of ≥ 4 mg/ml can be useful as a prospective inhibitory 
agent in breast cancers or can be doped as an adjuvant to standard chemotherapy. 
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CHAPTER 1 
  
 
INTRODUCTION 
 
 
1.1 Background Information 
 
The global prevalence of cancer has risen from 14.1 million diagnosed cases in 
2012 to 18 million in 2018, out of which 2 million (11.6%) was breast cancer (Bray et al., 
2018). Death rate worldwide was reported to be 9.6 million and breast cancer accounted 
for 6.6%. Cancer is a disease with uncontrolled manner of growth and migration of 
abnormal cells (Qi et al., 2017; Bai et al., 2018). The mutated oncogenes and tumour 
suppressor genes of cancer cause cells migration, avoid tumour suppression, withstand 
cell death, instigate angiogenesis, facilitate continuous replication and invasion and 
metastasis. These characteristics and phenomena give the scientific community a daunting 
challenge in treating cancer (Qi et al., 2017). Cancer have become the one of the highest 
causes of mortality after heart diseases (Qi et al., 2017). 
It is forecasted that there will be 19.3 million new cases per annually by 2025 
(Ferlay, J. et al., 2015). The prevalence of breast cancer is high in women globally. 
Around 1.7 million population is diagnosed annually and higher in developed countries as 
compared to developing countries, probably owing to growth and ageing (Ferlay et al., 
2015; Soerjomataram et al., 2012). However, there is sudden increase in the number of 
cancer cases in developing countries, which could be attributed to the change in lifestyle 
or lack of proper screening strategies. Although the mortality rate of breast cancer is 
almost equal to that of developed countries, which may be due to lack of early and  
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poorer diagnoses that results to late treatment. Survival rate is reported to be high in 
developed nations with sophisticated health care than in developing nations (Andreeva 
and Pokhrel, 2013; Bray et al., 2018; Torre et al., 2016). 
Breast cancer is the most common and is the leading cause of high mortality 
among women (Saha et al., 2015) responsible for roughly one third of all cancers (Wang 
et al., 2017). Globally, the magnitude of breast cancer continues to accelerate, resulting 
in the yearly reporting of new cases amounting to greater than a million, furthermore it is 
the second commonest cancers in the world and prevalent in all countries (Ghoncheh, 
Pournamdar and Salehiniya, 2016; Wang et al., 2017). The increase trend of breast cancer 
is foreseen achieving 3.2 million per annum by 2030 (Winters et al., 2017). One third of 
these cases are metastatic or locally advanced disease or recurrent cancer (Wang et al., 
2017). 
It is documented that breast cancer occurs 1 in every 8 women and accounts for 
14% of newly diagnosed cancers in United State (US), mostly in the age group of between 
55 to 64 years old (Winters et al., 2017). It was reported in US that about 40,450 deaths 
were due to breast cancer in 2016 (Winters et al., 2017). 
In Europe, about 465,200 of breast cancer cases are newly diagnosed yearly. New 
female cancer cases amount to 29% (Ferlay et al., 2015). The mortality is about 131,200 
annually and the cancer deaths of females is 17% (Ferlay et al., 2015). 
Developing nations like Africa have registered about 168,690 new cancer cases and 
experience 74,000 deaths at an incidence rate of 8% (Bray et al., 2018). This could be due 
to improper health system, lack of diagnoses or higher percentage of younger population 
in this region. 
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In Asia approximately 1.7 million new cancer were reported. It has been gauged 
that 1.2 million cancers mainly in the South East Asia region. Breast cancer is among the 
most prevalent cancers among women in this region (Bray et al., 2018). This region has 
the highest breast cancer incidence with 43.6% compared to all the other continents. 
Global cancer observatory (Globocan) documented the continent has 911,014 new breast 
cancer cases with a mortality of 310,577 (Bray et al., 2018). 
Malaysia has a population of about 29.2 million people. It was reported 15% 
mortality was due to cancers (Dahlui, M., Ramli, S. and Bulgiba, A.M., 2011). It is the 
third   highest cause of death in Malaysia. The 2006 National Cancer Registry disclosed 
3,525 female breast cancer cases and it is the most prevalent diagnosed cancer in females 
(Dahlui, M., Ramli, S. and Bulgiba, A.M., 2011). Breast cancer is the most common 
cancer among Malaysian women where 1 in 20 women is likely to develop breast cancer 
within her life time (Dahlui, M., Ramli, S. and Bulgiba, A.M., 2011).  Risk of breast 
cancer increased with the age particularly between the age of 50-59 years. There are many 
risk factors of developing breast cancer such as a past history that lead to primary breast 
cancer, breast carcinoma in situ, a tissue biopsy revealing migrative cells, can develop 
cancer in a near future or benign breast disease with an unusual enlargement is at greater 
risk of developing cancer (Dahlui, M., Ramli, S. and Bulgiba, A.M., 2011). 
Breast cancer is most common in women with a prevalence of 30% and is the 
leading contributor of cancer related death among women, although rarely seen in men 
(Bai et al., 2018). Breast cancer is a heterogenous disease that has many known 
biomarkers but still may not be limited to only these (Jézéquel et al., 2015; Turashvili and 
Brogi, 2017). Even though, lymph node metastases, histologic grade, expression of 
steroid and growth factor receptors, estrogen-inducible genes like cathepsin D, 
protooncogenes like ERBB2, and mutations in the TP53 gene have been associated to the 
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disease (Sørlie et al., 2001). Tumour can evolve and develop into malignant if not 
diagnose at the earlier stage (Ju, Zhu and Yuan, 2018).  Breast cancer has been analysis 
by many platforms to determine the molecular markers of the disease not only limited to 
Gene expression analysis which has  categories breast cancer into four distinct major 
molecular subtypes luminal A, luminal B, HER2-enriched, and basal-like (Curigliano et 
al., 2017). The luminal A and luminal B subtypes are found within ER+ breast carcinomas 
but better in terms of treatment than HER2-enriched and basal-like subtypes (Martin, 
Smith and Tomlinson, 2014; Dai et al., 2015; Jézéquel et al., 2015; Schiff, 2015; 
Turashvili and Brogi, 2017).  Despite all expressing ER+, luminal B tumours expressed 
more migration-associated genes and have substandard prognosis than luminal A 
tumours.  However, there are four main subtypes of breast cancer, hormonal receptor 
positive; estrogen receptor positive (ER+), progesterone receptor positive (PR+), human 
epidermal growth receptor 2 and triple negative breast cancer (Ding et al., 2018; Gray et 
al., 2017; Israel et al., 2018). The subtypes relate to certain morphological features and 
different clinical outcomes, showing that breast cancer is not a single disease. Breast 
cancer is a diversified disease with different biomarkers (Ju, et al., 2018). Tumour cells 
slowly developed resistance against treatment regimens. Combine treatment will work 
better but many side effects have been reported. With the advance of technology, there 
are many promising hopes to come up with a cure to breast cancer, even though it is 
difficult to find a single treatment to suit all the subtypes (Ju, Zhu and Yuan, 2018). 
 
To assess invasive breast cancer, molecular techniques are used. This will dictate 
the type of hormonal receptors or whether there is an overexpression of human epidermal 
growth factor receptor 2, estrogen or progesterone receptor positive.  The HER 2- is the 
second most prevalent subtype, lethal and poor predictable treatment outcome with high 
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risk of recurrence than the others. The HER2- subtype is denoted with high expression of 
HER2 and migration genes and encompass ER-/ PR-/HER2+ and ER+/PR+/HER2+ 
tumours (Dai et al., 2015; Turashvili and Brogi, 2017).  
Approximately 12% to 20% of invasive breast cancers depict HER2 gene 
amplification and/or protein overexpression and are corelated with poor prognosis and 
predictive of response to anti-HER2 targeted therapy. On the other hand, 10% to 15% of 
IBCs are ER, PR, and HER2 negative (triple-negative breast cancer [TNBC]), and lack 
targeted therapy currently (Tang and Tse, 2016). Triple-negative (TN) tumour, is 
common in primary breast cancer, known to be the most aggressive and deadly breast 
cancer subtypes. It lacks estrogen, progesterone and HER2 receptors, making its 
therapeutic management  challenging (Jézéquel et al., 2015).   
Triple-negative is a  molecular subtype to claudin-low, denoted by low expression 
of cell-cell adhesion cluster containing claudin 3, 4, 7 and E-cadherin, luminal and 
migration-associated genes, strengthen in epithelial-to- mesenchymal transition (EMT) 
features, immune system responses, and stem cell-associated biological processes 
(Jézéquel et al., 2015). 
A cost effective and less time-consuming immunohistochemistry staining method 
have also been used as a molecular subtype panel tool for breast cancer comprising ER, 
PR, HER2, Ki-67, epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK5/6) 
identifying the molecular subtypes of breast cancer.  The routine immunohistochemical 
(IHC) analysis for ER, PR, and HER2 provides critical prognostic and predictive 
information for Invasive Breast Cancer (IBC). Nearly 70% of IBCs are ER positive. PR 
is hugely contained by estrogen, and PR negativity is linked to decreased response to 
tamoxifen therapy. Therefore, IHC and/or in situ hybridization assays are used to 
6 
 
 
determine the subtypes of breast cancer. Tumours are also distinguished by grade and 
proliferative fraction usually by Ki-67 immunostaining (Curigliano et al., 2017). This 
knowledge is helpful in the diagnostic, prognostic, and therapeutic strategies for breast 
cancer. Regardless of this information, there is still unknown information in regard to 
tumour progression, as it is paramount knowing the driving factors for metastatic disease 
and treatment resistance. The use of these methods helps in projecting the response to 
chemotherapy and recurrence risk (Turashvili and Brogi, 2017).  
The commonest breast tumour during menopause period in women are estrogen 
receptor (ER)-positive and/or progesterone receptor (PgR)-positive in which endocrine 
therapy will be the choice of treatment like tamoxifen, aromatase inhibitors to interrupt 
with ER signalling and/or block estrogen production (Wu et al., 2016; Tang and Tse, 
2016; Curigliano et al., 2017).  Tamoxifen is  the standard endocrine treatment for these 
patients for couple of years  but currently the third-generation aromatase inhibitors (AIs) 
are also used because of its superior efficacy and tolerability profiles  (Tang and Tse, 
2016; Curigliano et al., 2017).   
Tamoxifen is still used, even though many clinicians use it further down the 
treatment sequence. Regardless of these changes in clinical practice, many patients with 
advanced breast cancer tumour encountered relapse or disease progression after endocrine 
treatment. Due to these there is necessity for, non– cross-resistant, well-tolerated agents 
that can be cooperated  into the endocrine treatment sequence (Faslodex and 
Pharmaceuticals, 2007). Invasive breast cancers (IBCs) are multi-disparity disease, 
revealing molecular, pathologic features and biologic behaviour. Morphologic 
classification, histologic grade, status of estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor-2 (HER2), and the stage of the tumour, 
are useful in guiding clinical management (Tang and Tse, 2016).  Estrogen receptor (ER), 
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progesterone receptor (PgR), Human Epidermal Growth Factor Receptor 2 (HER2) and 
ER and PgR are grouped together into the class of hormone receptors (HRs). ER 
expressed  in roughly 75% of breast cancer patients. (Curigliano et al., 2017). 
ER+ is the most prevalent and accounts for about 70% of breast cancer tumour. 
ER and its ligand, estrogen, plays a vital role in the development and the continuity of 
breast cancer. Endocrine therapies, target ER activity, treating ER+ breast cancer in the 
early and the metastatic stages. However, resistance is still common, and it significantly 
influences overall morbidity and mortality in patients (Schiff, 2016). 
Recent findings in ER provided the mechanisms contributing to alteration in ER 
signalling in endocrine- resistant tumours, inclusive of deregulated growth factor receptor 
signalling due to ligand- independent ER activation, unbalanced ER co-regulator activity, 
and genomic alterations in relation to the ER gene ESR1 (Schiff, 2015). The effects of 
estrogen/ER on cyclin D1  and c-Myc expression caused estrogen-stimulated cellular 
growth and migration (Mendes-pereira et al., 2012). 
  
This disease is a burden to the economy and the patients. It is the most prevalent 
cancer affecting women of all nations with high healthcare expenses. Additionally, death 
causes an annual productivity loss (Cun and Yang, 2018; Lucato et al., 2015). This will 
remain to be seen especially in developed nations with growing in ageing population 
(Bray et al., 2018). 
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1.2 Problem statement 
 
The role of chemotherapeutic agents is to induce cytotoxic effects on cancers cells. 
However, these agents are accompanied with side effects on normal tissues and organs 
(Qi et al., 2017). They can also cause bone marrow haematopoietic dysfunction, hair loss, 
nausea, fatigue and vomiting. Some of these drugs have low bioavailability and are 
unable to reach their targets. These are some of the factors that contribute to their failure 
(He et al., 2016; Qi et al., 2017). Combination chemotherapy has been used to overcome 
some of these limitations and proven to be more effective than single agent chemotherapy 
treatment. Nano co-delivery system of drugs where drugs with different physicochemical 
and pharmacological qualities are submerged into the delivery system has been developed  
to improve the effectiveness of the anticancer drugs and reach their target (Qi et al., 2017). 
 
Different anti-cancer chemotherapy drug have different mechanisms on tumour 
cells. The anti-microtubule alkaloid agents, for example vinblastine, prevent the 
formation of microtubules. Whereas taxanes like paclitaxel prevent the breaking up of the 
assemble microtubule (Qi et al., 2017; Varmaghani et al., 2014). Topoisomerase 
inhibitors (topotecan) are anti-cancer drugs that counter the activity of the enzyme by 
avoiding the over-winding or the under-winding of the DNA. Cisplatin, which is a 
platinum-based drug, blocks the multiplication of DNA. All chemotherapy drugs are used 
in many cancer treatments including breast cancer by preventing the complete mitosis of 
cancer cells or leading to DNA synthesis error facilitating the apoptosis of cancer cells. 
The current development of omics, antibodies and genes has improved anticancer therapy 
through their qualities in reaching targets in both pre-clinical and clinical application 
(Guo et al., 2017; Qi et al., 2017). 
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Despite all the challenges and problems with chemotherapy, it is still the best 
treatment option due to its less invasiveness, administered conveniently and effective in 
all ages. The poor uptake of these drugs and non-specific target distribution makes them 
ineffective (Qi et al., 2017). Furthermore, the dreadful effects such as the toxicity, 
resistance and restricted usage in clinics of single chemotherapeutic drug drive the needs to 
come up with a solution. Nanotechnology is used in the co-delivery of cancer drugs to 
yield better efficacy. Cancer cells are treated with this technology with less adverse effects 
in contrary to single chemotherapeutic treatment (Guo et al., 2017; He et al., 2016; Qi et 
al., 2017; Varmaghani et al, 2014). Nanotechnology has made it feasible for the delivery 
of anticancer drugs to the desired target. It disrupts the biological barrier, thereby 
penetrating cancer cells. Advancement of nanotechnology has assisted in the treatment 
efficacy against complicated cancer pathways. Efficient delivery to the targeted area with 
nano-drug co-delivery system (NDCDS) gives the possibility of drugs penetrating the 
blood circulation. With this technology, drugs are transported and released slowly to their 
targets (Guo et al., 2017; He et al., 2016; Hanauske et al., 1994; Qi et al., 2017; Wang et 
al., 2017). The treatment of malignant tumours with different regimens or ways had been 
explored but none of these strategies proves maximum achievement clinically. Bioactive 
glass has been investigated as result of its capabilities to deliver drugs effectively (Miola, 
M., Pakzad., 2018). 
 
This research was intended to study the induced effects cause by bioactive glass 
on tamoxifen parent and resistance MCF-7 breast cancer cell lines. The study will 
compare the anti-migration and the morphology (apoptotic) effects of MCF-7 parent and 
resistant cancer cells treated with bioactive glass. Bioactive glass was chosen because of 
its potentials in not only orthopaedics and dentistry field but also in other medical cadres 
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and has proven effective in both in vitro and in vivo studies in bone and tissues 
regeneration. It is used clinically for its antibacterial effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
1.3 Objectives 
 
 
1.3.1 Main Objective  
 
To compare the effect of bioactive glass (BG) on the migration and growth of 
parent and resistant breast cancer cells. 
 
1.3.2 Specific objectives 
 
 
I. To compare morphological changes before and after treatment using BG. 
II. To determine effects of BG in parent and resistant cells of BG and 
Vinblastine on cancer cells. 
III. To compare effects of BG with standard chemotherapy drug. 
1.3.3 Hypothesis 
 
 
Null hypothesis: Bioactive glass will not result in an anti-migration effect on 
Michigan Cancer Foundation 7 (MCF-7) cells and cause no morphological changes of the 
cells. 
Alternate hypothesis: Bioactive glass will result in an anti-migration effect on 
Michigan Cancer Foundation 7 (MCF-7) cells and cause morphological changes of the 
cells.
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CHAPTER 2  
 LITERATURE REVIEW 
An urgent need in cancer management is to develop effective and affordable 
approaches for early detection, diagnosis, and treatment especially in developing 
countries. It is critical and crucial to bring morbidity and mortality in line with progress 
made in recent years particularly in developed countries (Tarver, T., 2012.; Ferlay et al., 
2015). 
 
Over the past decades, there has been a lot of efforts and progress to tackle breast 
cancer (Ju, Zhu and Yuan, 2018). Existing treatment approaches such as chemotherapy, 
surgery and radiotherapy are intended to improve the life span and the quality of life (Qi 
et al., 2017). Nevertheless, with all the treatment options, the mortality rate is inconsistent. 
The treatment relapses of these uncontrollable inconsistent cancer may be due to presence 
of resistant traits that encourage micro metastasis and have the capabilities to cause 
recurrence, thus, there is a need to improve therapeutics for resistant breast cancer (Bai et 
al., 2018; Ju, Zhu and Yuan, 2018). 
 
However, these treatment options depend particularly on the subtype of cancer and need 
careful selection (Tarver, T., 2012; Ferlay et al., 2015). According to studies, breast 
cancer survival rate is more in the early stage of cancer but also depends on the stage, 
clinicopathological features and the subtypes of cancer (Bai et al., 2018; Winters et al., 
2017).  Additionally, chemotherapy relapse of breast cancer has been proven (Lucato et 
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al., 2015; Winters et al., 2017). Tamoxifen is a selective estrogen receptor modulator 
that has been indicated to be able to reduce the risk of breast cancer (Bai et al., 2018; 
Winters et al., 2017). 
 
2.1 Tamoxifen 
 
According to (the American Society of Clinical guidelines of Oncology) 
tamoxifen reduces the risk of invasive and metastasis breast cancer particularly in those 
with ER+, premenopausal or those above 35 years or in situ lobular carcinoma (Lucato et 
al., 2015; Winters et al., 2017). The MCF-7 resistant cells line used in the research 
obtained its resistance due to been continuously cultured with 1 µM 4-OH-tamoxifen for 
8-12 months. 
Chemotherapies that targets estrogen signalling yielded to reducing mortality 
from breast cancer. However, resistance to tamoxifen countered these achievements. 
Multiple genes are associated to resistance or sensitivity to tamoxifen. Combining whole-
genome shRNA screening to RNA interference reagents targeting revealed genes on the 
cellular response to tamoxifen. Furthermore, silencing certain genes results to tamoxifen 
resistance (including BAP1, CLPP, GPRC5D, NAE1, NF1, NIPBL, NSD1, RAD21, 
RARG, SMC3, and UBA3) and equally the silencing of their genes contributes to the 
causes sensitivity to this endocrine agent (C10orf72, C15orf55/NUT, EDF1, ING5, 
KRAS, NOC3L, PPP1R15B, RRAS2, TMPRSS2, and TPM4). Genes like NF1, a 
regulator of RAS signalling, relating  with clinical outcome after tamoxifen treatment 
(Mendes-pereira et al., 2012). 
Endocrine therapy is used as a frontline treatment for hormone receptor-positive breast 
cancer, while trastuzumab for HER2-positive cancers. Traditional cytotoxic 
chemotherapeutics, like taxanes and anthracyclines are used in combination with specific 
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therapies as frontline therapies for triple-negative breast cancer. Th mechanisms behind 
the resistance to the various therapeutics are many and not fully comprehended. But, 
Phosphatidylinositide 3-kinase (PI3K)/Akt pathway, miRNAs, and epigenetic alterations  
in breast cancer are associated to multidrug-resistant phenotype (Mendes-pereira et al., 
2012; Martin, Smith and Tomlinson, 2014). ER induces gene activation during 
transcription by nuclear translocation after ligand binding or can phosphorylation in the 
absence of ligand. ERs may also associate with the plasma membrane in the presence of 
SRC and other adaptor proteins. At this stage, ligand binding enhances nongenomic 
effects via activation of signalling pathways, including the Pi3K/Akt and the Ras/MAPK 
pathways. These pathways are also trigger by ligand binding to the GPR30 and by growth 
factor binding to receptor tyrosine kinases, including HER2, activating 
autophosphorylation and downstream signalling. The Pi3K/Akt pathway  as predicted is 
a meeting point in the mechanisms implicated in drug resistance (Martin, Smith and 
Tomlinson, 2014).   
 It is stated that ERα phosphorylation has an impact in patients who have breast 
cancer. As higher level of ERα S167 and/or S118 phosphorylation is a signed of positive 
outcome in patients treated with tamoxifen therapy. In contrary,  ERα S305 is  associated  
to aggressiveness of tumours in which PKA and PAK1 are the possible candidates (Wei 
et al., 2014). 
Resistant tumours causes changes in their intrinsic metabolic pathways over a long 
period of treatment to maintain survival and  growth (Blundon and Dasgupta, 2019). 
 Estrogen G-protein coupled receptor (GPR30) signalling pathway up-regulation 
can elucidate the rise sensibility of TAM-R cells to GPR30-specific agonist G1 in MCF-
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7 cells. The overexpression of GPR30 enhance the accelerated development of resistance 
if the natural ligand is presence (Ignatov et al., 2010). 
Most breast malignancies are ER+. Tamoxifen is the standard drug treating such 
cases. Overall, outcome is promising but recurrence is still reported in patient with natural 
resistance, while some acquired resistance (S.S. Malik et al., 2018). It was reported that 
among patients with metastasis cancer, about 40% received tamoxifen as adjuvant therapy 
but encountered failure. Furthermore, patients with menopause who were treated earlier 
may have recurrent tumours and could become resistant to tamoxifen with time (Rondón-
Lagos et al., 2016). 
 
2.2 Vinblastine 
 
Vinblastine (VB) is a vinca alkaloid with antineoplastic properties. It is divided 
into vindoline and catharanthine. They have been used as antitumour agents for 
decades (Amiri, B., et al., 2018). They are derived from Catharanthus roseus leaves. 
Besides anticancer, these compounds also exhibit an antileukaemic effects (Amiri, B. 
et al., 2018). Vinblastine causes cancer cell apoptosis and cell arrest which is enhanced 
by reactive oxygen species (ROS) (Lee et al., 2016; Varmaghani, et al., 2014). It 
obstructs the nucleic acid and protein production by preventing glutamic acid 
utilisation (Amiri, B., et al., 2018). Vinblastine targets the tubulins of cancer cells 
destabilising polymerisation and depolymerisation, thus influencing cell death (Amiri, 
B., et al., 2018;  Lee  et al., 2016).  Microtubules are very important in cell functioning 
as they are involved in organising the cytoskeleton structure of eukaryotic cells, 
separation of cell division, internal cell trafficking, cell motility and the formation of 
flagella as well as cilia. Microtubules are a key treatment target in the development of 
drugs (Lee  et al., 2016; Wang  et al., 2019). The migration of cell is an important 
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physiological process including wound healing, tumour invasion, metastasis and neo-
angiogenesis (Wang  et al., 2019). In cell migration, loosen shape microtubules are 
first formed, which facilitate Rho protein to enhance an unbalanced actin shrinking and 
substrate adhesion. This results in difference and directional motility of cells (Wang  
et al., 2019). Vinblastine causes the deceleration of the microtubules, which causes 
their disability. Furthermore, there are other molecules that contribute to the binding 
of vinblastine to the tubulin. These molecules form and trigger the formation of a 
complex (Varmaghani, et al., 2014). The issues of multidrug resistance, neurotoxicity 
and risk of severe side effects have caused a setback in the positive impact of 
vinblastine clinically. Due to this, the use of a delivery system which will help in drugs 
reaching their target in a controlled manner is needed. It is postulated that drug 
formulation using nanotechnology will solve this issue. Nanoparticles are vehicles 
suitable to transport drugs due to their biocompatibility, biodegradable, non-
immunogenic and stability (Amiri, B.,  et al.,  2018). 
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2.3 Metastasis Breast Cancer 
 
Metastatic disease leads to 90% of mortality in cancer. It is a challenge as there is 
no regimen that would permanently cure metastatic cancer (Meirson and Gil-Henn, 2018). 
Metastatic cancer spreads from the point of origin to other tissues via the bloodstream. 
Cancer cells form invadopodia and travel across these tissues (Meirson and Gil-Henn, 
2018). 
Metastasis is the process in which the primary tumour permeate the tissue around 
the tumour and colonise other sites of the body. Migration occurs because loss of cell to 
cell adhesive ability and disconnection from the primary tumour. Change in the matrix 
cohesion properties and release of substances that breaks the matrix support the process 
of tumour cell invasion. Tumour cells enter into the blood vessel or indirectly via the 
lymphatic system. They are distributed faster through lymphatic system rather than 
through the blood circulation (Nandy and Lakshmanaswamy, 2017). Cytokines were 
found to play a role in cancer progression and migration. They are involved in 
inflammatory responses, cell interaction, metastasis and angiogenesis (Nandy and 
Lakshmanaswamy, 2017). 
Metastatic cells run into lot of physical forces along the whole process such as the 
one extracellular matrix pose on primary tumour cell and circulating tumour cells come 
across many haemodynamic forces. This pressure can lead to the Linker of 
Nucleoskeleton and cytoskeleton (LINC) complex being compromised and deforms the 
nucleus and weakens the cytoplasm. 
Alteration of the Lamin A/C is seen in breast cancer which can result in the 
mutation of LINC-mediated linkage between the cytoplasm and the nucleus, causing 
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invasiveness of tumour cells due to the weakened cytoplasm and the nucleus (Nandy and 
Lakshmanaswamy, 2017). 
Metastasis of cancer cells also depends on the microenvironment. 
Microenvironment supports and encourages the invasion and metastasis of cancer cells 
(Nandy and Lakshmanaswamy, 2017). Interaction between tumour cells and 
microenvironment is key in determining the speed of cancer progression, invasion and 
metastasis. It has been noticed that micro-environment frequently changes during tumour 
cell signalling. The active nature of micro-environment immensely affects the whole 
mechanism of metastasis (Nandy and Lakshmanaswamy, 2017). 
Notwithstanding of all the improved technologies in the early diagnoses of   breast 
cancer, locally advanced breast cancer (LABC) is prognose poor diagnosis, contributing 
to 30-60% of newly diagnosed breast cancer cases in underdeveloped nations. LABC is 
characterised by different diseases with advanced primary tumours, advanced nodal 
disease and inflammatory carcinomas (Saha et al., 2015).  High percentage of treatment 
failures after initial responses to chemotherapy indicates drug resistance is an obstacle for 
managing patients with LABC. 
Overexpression of apoptosis inhibitor survivin contributes to tamoxifen 
resistance. It has been seen that minimal level of survivin prolongs the overall survival 
time after treatment (Marcotte et al., 2017; Cheung, C.H.A., et al., 2010). It is also found 
in prostate cancer, where its predominance is related to metastasis (Hei et al., 2010; 
Cheung, C.H.A., et al., 2010). 
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2.4 Bioactive glass 
 
Cytotoxic anticancer drugs have become ineffective due to drug resistance, that 
contributes to deaths of many women affected with breast cancer. High expression of 
adenosine triphosphate binding cassette (ABC)-transporters is shown to be link to 
resistant breast cancer (Wang et al., 2014). The promising avenue of tackling this menace 
problem is the use of nanocarriers by endosomal delivery of drugs. Doxorubicin (DOX) 
an anthracycline antibiotic used for breast treatment is been used with mesoporous silica 
nanoparticles on MCF-7 cells. It has showed the capability of overcoming of the 
resistance of MCF-7 breast cancer cells when DOX is embedded in mesoporous silica 
nanoparticles (Wang et al., 2014). It is been seen that bioactive glass of different powders 
have shown cytotoxicity at a concentration of greater than 5 mg/ml (Rismanchian, 
Khodaeian and Bahramian, 2013). Albumin nano-carrier for delivery of CuNPs have 
proven to be an effective anticancer treatment for invasive breast cancer cells due to its 
high toxicity and induced apoptosis cell death when compared to normal cells (Azizi et 
al., 2017). Nanocarriers are used as a targeted therapy on cancer cells and more useful 
than other methods (Burge, P., Rohr, C. and Daly, A. 2017).       
Studies have demonstrated the idea of using nano-techniques of alleviating and replacing 
defects and damaged parts of patients’ body. The invention of 45S5 Bioglass has changed 
the concept that implantable materials should be inert. Bioactive glass is predominantly 
used in tissue engineering field due to their abilities to bond to living tissues and induce  
tissue regeneration and growth as its dissolves with time (Baino, Novajra and Boccaccini., 
2016). Bioglass precursors have been utilised in clinical settings since in the nineteen 
centuries like Perioglas and currently NovaBone useful for orthopaedic and dental 
application (Baino, Novajra and Boccaccini, 2016). Since its invention, bioactive glass 
has been used in a variety of field different from bone application. BG has been also 
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studied and applied in many medical fields, including wound dressings, drug delivery 
systems, and other pharmaceutical applications (Jebahi, S.  et al., 2013). In justification, 
it has been applied in neuromuscular, artificial cornea, cardiac tissue engineering, 
treatment of gastric ulcers, non-osseous cancer therapy. It has been shown efficient in 
wound treatment and proven to be faster in wound healing bioactive glass treated wounds. 
Other BG-base products are used in wound healing and nerve regeneration and Ag- doped 
phosphate glasses with polymeric adhesive have been used for the treatment of wound 
(Baino, et al., 2018). Bioactive glass ointments show shortened wound healing time and, 
enhanced migration of fibroblasts and tissue growth (Baino, Novajra and Boccaccini, 
2016).  BG  enhances and induces the growth and maturation of osteoblasts and nurtures 
the expression and preservation of the osteoblastic phenotype. Furthermore, BG promotes 
multipotent bone marrow stromal cell functions. Moreover, the osteoprogenitor cells 
proliferate and differentiate to matrix-producing osteoblasts (Baino, Novajra and 
Boccaccini, 2016; Jebahi., et al., 2013). 
Bioactive glass has been used as a delivery system especially in the treatment of 
deadly inoperable type of malignant tumours (Lin, Mauro and Kaur, 2019). The treatment 
of cancers and many disease conditions today fail due to non-specific targeted treatment. 
Due to this, tumour treatment has been revolutionised by using targeted drug delivery 
system for cancer therapy, which has reduced the adverse effects of chemotherapy to 
healthy cells (Lin, Lin and Chan, 2013). Targeted delivery therapy will enhance the 
effectiveness of cancer treatment. Coating of drug carriers to specific binding factors or 
receptors can increase the efficacy of drugs as there will be high uptake of the drug. 
Currently, drug delivery systems such as mesoporous silica, polymers and liposomes to 
target cancer cells are used (Lin, Lin and Chan, 2013). 
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 Folate conjugated mesoporous silica with doxorubicin drug is used as a targeted 
cancer therapy and improves cytotoxicity than when the drugs are used alone. Folate 
grafted mesoporous silica particles induce cancer cells to take more drug. Bioactive glass 
is used in the treatment of bone-tumour cancer therapy (Lin, Lin and Chan, 2013). 
Bioactive glass incorporated with lysozyme (LY) increases its function and forms 
hydroxyapatite in body fluid. LY bioactive glass acts as an antibiotic in treating gram 
positive B. subtilis.  Synthesised Ag-loaded with mesoporous bioactive glass also have 
antibacterial effects by discharging ions from Ag-MBGs (Fan et al., 2015).  LY bioactive 
glass equally proves cytotoxicity against hepatocellular carcinoma cell line. LY bioactive 
glass is useful for biomedical application especially for the treatment of bone tumours 
(Zheng et al., 2016).  
Small amount of cancer drugs reach to their targets and the rest are distributed in 
the body which could affect normal healthy organs. Anticancer drug like 5-fluorouracil 
(5-FU) is used in the management and treatment of many cancers but has a short half-life 
due to being metabolised fast by the body and non-specific. Increased efficacy could be 
achieved if loaded with nanoparticles. The drug can be maintained and released gently, 
thus preventing the recurrence of tumours after surgery (El-Kady and Farag, 2015). 
Bioactive glass has been used in cancer cell removal (Kargozar et al., 2018a). Magnetic 
bioactive glasses (MBGs) are used in the treatment of deep bone cancer tumours (Lin, 
Mauro and Kaur, 2019).  The qualities of MBG especially with DOX allow it to function 
well in cancer treatment and their applicable for bone cancer  treatment (Wu, C., Fan, W. 
and Chang, J., 2013). 
Radiation have been a conventional treatment for cancer which could bear some 
consequences to the patients. However, in situ radiation of high dose had been 
instrumental in the treatment of cancers for a minimal period without harming the patient. 
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Internal therapeutic irradiation of radioisotope in biocompatible glass beads injected to 
patients has been fruitful with high durability and are able to reach to the organs to be 
treated (Baino, Novajra and Boccaccini, 2016).  
Recently, radioactive glass microspheres (TheraSphere®) are medically used in 
the treatment of hepatocellular carcinoma and metastatic liver cancer (Baino, Novajra and 
Boccaccini, 2016).  Radioactive glass microspheres are medically used for the treatment 
of unresectable hepatocellular carcinoma, metastatic liver cancer and 
cholangiocarcinoma. The approach involves the submerging of radionuclide in protective 
insoluble microcapsules that are injected into the patient’s body and targeting cancer cells 
like in the case of treating prostate cancer using 142Pr glass seeds (Baino, Novajra and 
Boccaccini, 2016., Baino et al.,2018). Biocompatible radioactive glasses has been applied 
for the treatment of liver cancer. Insoluble yttrium oxide (Y2O3– Al2O3–SiO2) glass 
microspheres with diameter of 25 µm are injected into the patient and they are anchored 
in the capillary bed of the diseased liver. This will be discharged towards tumour cells that 
is tolerated by the patient. Radioactive glass has also been used in patients with metastatic 
colorectal carcinoma (Baino et al.,2018). This therapeutic approach leads to a significant 
improvement of survival times and quality of life for the patients. Iron oxide magnetic 
nanoparticles (Fe3O4, MNPs) are used in the treatment of cancer. Iron oxide nanocrystals 
simultaneously loaded with docetaxel, have been shown to have more efficacy of 
anticancer drug. The targeted nanoparticles showed an antimigrative effect in prostate 
cancer cells on cytotoxicity assay in a dose dependent manner (Namvar, F. et al., 2014). 
Mesoporous bioglass nanospheres incorporated with alendronate have the capability to 
control osteosarcoma cells and osteoclast activities (Boanini et al., 2016). Magnetic 
bioceramics and nanoparticles in situ have been utilised, especially calcium phosphate 
bone cement in the treatment of bone tumours by exciting hyperthermic and replacing 
23 
 
 
fracture bone. Evidence in clinical studies has proven in situ implant treatment of 
metastatic bone tumour (Cochis, Miola and Bretcanu, 2016; Miola et al., 2018). The 
positivity of the clinical application of this biomaterial is high but further research is still 
needed to fully comprehend the mechanism involved in the treatment of cancer. 
Furthermore, more in vitro and in vivo studies on the effects of bioglass and glass ceramics 
are needed (Miola et al., 2018).   
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2.4.1 Biomaterials 
Biodegradable synthetic plastic and metal are made to replace natural bone 
recently but are weak as they cannot support the regeneration of load bearing bone. 
Metallic implant is non-self-repairable and cannot withstand the changing condition of 
the body due to the strong and stiffness of metal, breaking the normal process of bones 
and become less desirable at the long run. The used of calcium phosphate-based bio- 
ceramics and bioactive glass even though they are breakable but stronger than polymeric 
scaffolds, yield to the advance investigation and production of these biomaterials 
(Boccardi, et al., 2017; Fu, 2019; Hench et al., 2015; Jones, 2015a; Sepulveda et al., 2002) 
 
Biomaterials are any natural or synthetic material (metal or polymer) that are 
suitable to be introduced into living tissue or body for medical benefits either to treat, 
repair or substitute a tissue function of the body. After all the recent breakthrough, 
autograft is still the preferable standard for bone defect treatment. Allograft which is the 
second option to autograft is expensive and can be risky. Biomaterials are grouped in 
class A and class B. Class A (Bioactive glass) materials can produce bones by triggering 
responses both intra and extracellular at the contact point (Dziadek et al., 2016; Jones, 
2015b). Biomaterials have been used to replace autograft and allograft but are yet to meet 
the standard of a natural bone. Biomaterials used as templates for the repair and   
regeneration of bones and tissue should meet special criteria that are paramount in 
optimising tissue formation. Biomaterials should promote migration and pose no harm to 
both in vivo and in vitro tissues and should be degradable, neither be toxic on harmful to 
human body or should not trigger any reaction (Jones, 2015b). They can induce immature 
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cells into osteoblast. Biomaterials glass should be in three-dimensional structure with 
ability and potentials to triggering new bone growth and blood supply. The bone graft 
should be able to support the functional stresses of the substituted bone. Moreover, they 
should be able to converts the Hydroxyapatite (HA) at a quicker rate to a rate equal to the 
new bone ingrowth (Bi et al., 2014; Fu, 2019; Jones, 2015a). 
2.4.2       Bioactive Glass 
The BG was invented by Hench et al., 2015 and known as BG 45S5 has been 
widely used for tissue engineering (Hench et al., 2015). From the time of the discovery 
in the 70s, bioactive glass has been studied for its efficacy in bone tissue repair and 
substitution capability. This 3D structure accelerates the formation of hydroxycarbonate 
apatite layer after forming a bond with bones. This layer forms around implant facilitate 
their degradation and absorption (Lin et al., 2018). Inorganic oxide mixtures of various 
percentages have been used to produce divergent families of glasses. In addition to 
network-forming, network-modifying and intermediate oxide, BG production involves 
three types of inorganic oxides (Kargozar et al., 2018b). They are classified into silicate, 
borosilicate, borate and phosphate-based glasses. Apart from that, doped glasses and 
mesoporous BG are grouped as other classes of BG family. BG in modern medicine is 
used for repair and regenerative purposes (Kargozar et al., 2018b). It is not enclosed by 
tissues when embedded which making it useful in the clinical settings. Components of the 
bioactive glass chemically bind with host tissues, degrading as it is dissolving thereby 
releasing ions that will trigger or stimulate the formation of hydroxyapatite layer at its 
surface (Zain, N.S.M et al., 2016; Vichery and Nedelec, 2016). The treatment of bone 
defects is either through grafting which generates another wound to the bone tissue or 
implantation with metals which causes fibrous encapsulation. Since the invention of 
